Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other financing activities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other financing activities for 13 consecutive years, with $283000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities rose 87.42% to $283000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $649000.0, a 48.0% decrease, with the full-year FY2025 number at $576000.0, up 110.99% from a year prior.
  • Other financing activities was $283000.0 for Q4 2025 at Aytu Biopharma, up from $114000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $3.1 million in Q4 2022 to a low of -$5.1 million in Q2 2023.
  • A 5-year average of $176157.9 and a median of $283000.0 in 2025 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: skyrocketed 149.55% in 2022, then plummeted 33793.33% in 2023.
  • Aytu Biopharma's Other financing activities stood at $1.2 million in 2021, then surged by 149.55% to $3.1 million in 2022, then crashed by 73.26% to $820000.0 in 2023, then crashed by 81.59% to $151000.0 in 2024, then skyrocketed by 87.42% to $283000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other financing activities are $283000.0 (Q4 2025), $114000.0 (Q3 2025), and $113000.0 (Q2 2025).